Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.

07:00 EST 7th March 2013 | BioPortfolio

Summary of "Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria."

Many patients with chronic idiopathic urticaria (also called chronic spontaneous urticaria) do not have a response to therapy with H-antihistamines, even at high doses. In phase 2 trials, omalizumab, an IgE monoclonal antibody that targets IgE and affects mast-cell and basophil function, has shown efficacy in such patients.


Department of Dermatology and Allergy, Charité-Universitätsmedizin, Berlin.

Journal Details

This article was published in the following journal.

Name: The New England journal of medicine
ISSN: 1533-4406
Pages: 924-35


DeepDyve research library

PubMed Articles [25566 Associated PubMed Articles listed on BioPortfolio]

Home Self-Administration of Omalizumab for Chronic Spontaneous Urticaria.

Omalizumab is an anti-IgE monoclonal antibody, which is licensed as add-on therapy for chronic spontaneous urticaria (CSU)(1) . Although it provides effective symptomatic control, omalizumab does not ...

What are the effects of omalizumab in refractory chronic spontaneous urticaria?

Chronic spontaneous urticaria is a disorder mediated by mast cells, characterized by the development of wheals, angioedema or both, lasting six weeks or more, with or without a known trigger agent. Fi...

Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria.

This supplement reports proceedings of the second international Global Urticaria Forum, which was held in Berlin, Germany in November 2015. Omalizumab is approved for the treatment of chronic spontane...

Angioedema in the omalizumab chronic idiopathic/spontaneous urticaria pivotal studies.

Angioedema, present in some patients with chronic idiopathic/spontaneous urticaria (CIU/CSU), may have a negative effect on patient quality of life.

Cost Utility of Omalizumab Compared with Standard of Care for the Treatment of Chronic Spontaneous Urticaria.

Chronic spontaneous urticaria (CSU) negatively impacts patient quality of life and productivity and is associated with considerable indirect costs to society.

Clinical Trials [5528 Associated Clinical Trials listed on BioPortfolio]

A Study to Assess the Efficacy and Safety of Omalizumab Through 48 Weeks in Participants With Chronic Idiopathic Urticaria (CIU)

This randomized, double-blind, placebo-controlled study will evaluate efficacy and safety of subcutaneous omalizumab as an add-on therapy through 48 weeks. After completing an initial 24-w...

OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients

This trial will assess the efficacy of optimized re-treatment therapy with omalizumab (150mg or 300mg) after relapse, in patients with Chronic Spontaneous Urticaria who were clinically wel...

Effect of Anti-IgE in Chronic Urticaria

This study is being done to find out if a drug called Xolair (omalizumab), an anti-IgE antibody, is safe and effective for people with chronic urticaria (hives) with persistent symptoms in...

Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation

The proposed research is intended to determine if supplementation of relatively high dose vitamin D in chronic urticaria patients receiving omalizumab will result in continued symptomatic ...

CUTE (Chronic Urticaria Treatment Evaluation)

A study to compare the clinical efficacy and safety of Levocetirizine vs. Desloratadine in patients suffering from Chronic Idiopathic Urticaria (CIU) measured by the mean pruritus severity...

Medical and Biotech [MESH] Definitions

A long-acting, non-sedative antihistaminic used in the treatment of seasonal allergic rhinitis, asthma, allergic conjunctivitis, and chronic idiopathic urticaria. The drug is well tolerated and has no anticholinergic side effects.

A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects.

A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.

A spontaneous diminution or abatement of a disease over time, without formal treatment.

Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria.

Quick Search

DeepDyve research library

Relevant Topic

The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

Searches Linking to this Article